
New biotech facility to bring 350 jobs to Dublin
pharmafile | February 14, 2018 | News story | Manufacturing and Production, Research and Development | Dublin, Ireland, MSD, pharma
MSD has announced plans to invest in a new biotechnology facility in Dublin which it claims will create 350 jobs in the Irish capital.
The plant will be built on property the company already owns – the site of its former facility in Swords, which was closed down in June last year, taking with it 570 jobs since 2013.
The news shows that MSD is committed to bolstering its operations in Ireland. The company already employs more than 1,700 staff across four sites in Dublin, Carlow, Cork and Tipperary, with operations in the country generating $5.8 billion in 2016.
Last year, the firm announced plans to invest just under $350 million in its Carlow and Cork sites by 2020.
The move is part of a global investment plan to the tune of $12 billion which the company announced this month, around $10 billion of which will be spent in the US.
“This investment by MSD is a great vote of confidence in Ireland. MSD has been a tremendous success story in this country with plants located in several centres, providing valuable employment,” commented Speaking Ireland’s Minister for Business, Enterprise and Innovation, Heather Humphreys. “This new, cutting edge, Biotechnology facility will be a tremendous asset to our Pharma industry and will deepen the great partnership between the company and Ireland.”
Matt Fellows
Related Content

Smurfit Westrock unveils new clinical packaging facility at Dublin Airport
Smurfit Westrock has inaugurated the first-of-its-kind adherence and clinical packaging facility, reinforcing Ireland’s role at …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …






